Fulgent Genetics (FLGT) Stock Price, News & Analysis

Company Overview

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics. The company offers both clinician-ordered and direct-to-consumer testing models, as well as custom research services for biopharmaceutical partners and academic institutions. Through proprietary automation and AI-driven analytical pipelines, Fulgent aims to maintain cost-effective operations and high data quality for clients across the United States and select international markets.

Founded in 2011 by Ming Hsieh, Fulgent Genetics completed its initial public offering in 2019, expanding its capacity and geographic reach. Under the leadership of founder and chairman Ming Hsieh and an experienced management team, the company continues to invest in laboratory automation, informatics enhancements and strategic partnerships. Fulgent remains committed to regulatory compliance, quality assurance and ongoing innovation in molecular diagnostics to support personalized medicine and population health initiatives.

Key Stats

• Today's Range: $16.05 to $17.51
• 50-Day Range: $16.55 to $21.39
• 52-Week Range: $13.46 to $31.04
• Volume: 1.32 million shs
• Average Volume: 225,790 shs
• Market Capitalization: $470.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Hold

Fulgent Genetics Stock Analysis - MarketRank™

Fulgent Genetics scored higher than 43% of companies evaluated by MarketBeat, and ranked 544th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Fulgent Genetics has a consensus price target of $27.00, representing about 63.1% upside from its current price of $16.55.

Amount of Analyst Coverage

Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fulgent Genetics are expected to grow in the coming year, from ($2.81) to ($2.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulgent Genetics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulgent Genetics is -5.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulgent Genetics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.19% of the float of Fulgent Genetics has been sold short.

Short Interest Ratio / Days to Cover

Fulgent Genetics has a short interest ratio ("days to cover") of 11.43, which indicates bearish sentiment.

Change versus previous month

Short interest in Fulgent Genetics has recently increased by 4.82%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulgent Genetics does not currently pay a dividend.

Dividend Growth

Fulgent Genetics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.22

News Sentiment

Fulgent Genetics has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

5 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $106,360.00 in company stock.

Percentage Held by Insiders

36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 7/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:FLGT
• CIK: 1674930
• Web: www.fulgentgenetics.com
• Phone: (626) 350-0537
• Fax: 626-454-1667
• Employees: 1,315
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Fulgent Genetics: $27.00
• High Price Target: $36.00
• Low Price Target: $15.00
• Potential Upside/Downside: +63.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.51 million
• Net Margins: -26.05%
• Pretax Margin: -26.31%
• Return on Equity: -4.82%
• Return on Assets: -4.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.31
• Quick Ratio: 5.31

Sales & Book Value

• Annual Sales: $322.67 million
• Price / Sales: 1.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $35.80 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 28,400,000
• Free Float: 18,126,000
• Market Cap: $470.02 million
• Optionable: Optionable
• Beta: 0.89